Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

1055 results about "B cell" patented technology

B cells, also known as B lymphocytes, are a type of white blood cell of the small lymphocyte subtype. They function in the humoral immunity component of the adaptive immune system by secreting antibodies. Additionally, B cells present antigen (they are also classified as professional antigen-presenting cells (APCs)) and secrete cytokines. In mammals, B cells mature in the bone marrow, which is at the core of most bones. In birds, B cells mature in the bursa of Fabricius, a lymphoid organ. (The "B" from B cells comes from the name of this organ, where it was first discovered by Chang and Glick, and not from bone marrow as commonly believed).

Monoclonal antibody for resisting human hepatitis B e antigen and application thereof

The invention discloses an anti-human hepatitis B e antigen monoclonal antibody and application thereof, and relates to the technical field of hepatitis B detection. In a heavy chain variable region of the monoclonal antibody, an amino acid sequence of a complementarity determining region CDR1-3 is as shown in SEQ ID NO.1-3 or has at least 95% of homology with the sequence as shown in SEQ ID NO.1-3; in the light chain variable region, amino acid sequences of complementary determining regions CDR1 and CDR3 are shown as SEQ ID NO.4 and SEQ ID NO.5 or have at least 95% of homology with the sequences shown as SEQ ID NO.4 and SEQ ID NO.5, and an amino acid sequence of a complementary determining region CDR2 is FAS. The monoclonal antibody provided by the invention can well recognize a natural hepatitis B e antigen, and the titer of a supernatant cultured by a B cell can reach 1: 10000, so that the monoclonal antibody can be completely applied to detection research of the human hepatitis B e antigen. The chemiluminescence reagent prepared by using the monoclonal antibody has the advantages of high specificity, strong anti-interference capability, high detection sensitivity, good stability and the like, almost has no leak detection, and can replace an imported reagent.
Owner:武汉勖瑞生物科技有限责任公司

Rabbit-derived recombinant monoclonal antibody for specifically recognizing type II grass carp reovirus VP4 protein, eukaryotic expression method and application

The invention belongs to the technical field of immunology and in vitro diagnosis, and particularly relates to a rabbit-derived recombinant monoclonal antibody for specific recognition of type II grass carp reovirus VP4 protein, an eukaryotic expression method and application. According to the invention, a target gene S6 is transfected to an HEK293 cell for expression and purification, a New Zealand white rabbit is immunized in cooperation with a Freund's adjuvant, and the rabbit-derived recombinant monoclonal antibody capable of specifically recognizing the GCRV-II VP4 protein is obtained by using ELISA, single B cell screening and eukaryotic expression technologies. The antibody has strong specificity, provides support for further establishment of a specific II-type grass carp reovirus diagnosis technology, and has great application value in development of GCRV-II related scientific research.
Owner:INST OF AQUATIC LIFE ACAD SINICA

Anti-human CD3 rabbit recombinant monoclonal antibody as well as preparation method and application thereof

The invention relates to the technical field of biological medicines, and particularly discloses an anti-human CD3 rabbit recombinant monoclonal antibody as well as a preparation method and application thereof. The antibody obtains anti-CD3 immune response by immunizing a rabbit, is obtained by combining single B cell sorting, gene cloning and a mammalian cell expression system, and has high affinity and good specificity. The antibody can effectively recognize CD3 positive T cells in human peripheral blood and can be applied to the fields of flow cytometry, immunohistochemistry, T cell function research and the like. Experimental results show that the antibody has the advantages of high titer, strong fluorescence signal, low background and the like, and is superior to the traditional murine anti-CD3 antibody. Amino acid sequences of light chain and heavy chain variable regions of the antibody are further obtained, and controllability and repeatability of antibody expression are achieved. The antibody has important scientific research value and industrial application prospect, and is suitable for various scenes such as T cell marker detection, immune state evaluation, immunotherapy auxiliary research and the like.
Owner:JIANGSU ATAS BIOTECHNOLOGY CO LTD

Preparation method and application of anti-human MUC1 antibody

The invention relates to the technical field of biology, in particular to a preparation method and application of an anti-human MUC1 antibody, and provides a recombination system which utilizes an in-vitro B cell culture technology, uses ELISA (enzyme-linked immunosorbent assay) to detect the expression condition of the antibody, performs flow detection on the binding capacity level with cells and performs antibody expression and assembly through an expression vector. The monoclonal antibody with high specificity and strong affinity is screened out, and the immunogenicity is reduced on the basis that the high affinity combined with the antigen is reserved through humanized transformation, so that the monoclonal antibody is favorably applied to immunotherapy of a human body; the anti-human MUC1 antibody prepared by the invention plays an important role in immunotherapy of tumors, and solves the technical problems of insufficient specificity and lower affinity of the MUC1 antibody in the prior art.
Owner:SHANGHAI ENTEBIO PHARMACEUTICAL TECHNOLOGY CO LTD

Mouse anti-pelteobagrus fulvidraco IgM monoclonal antibody, hybridoma cell strain and application

The invention belongs to the field of monoclonal antibodies, and particularly relates to a mouse anti-pelteobagrus fulvidraco IgM monoclonal antibody, a hybridoma cell strain secreting the monoclonal antibody and application, a CDR region of a heavy chain variable region of the mouse anti-pelteobagrus fulvidraco IgM monoclonal antibody comprises three sequences shown in SEQ ID NO.1-3, and a CDR region of a light chain variable region of the mouse anti-pelteobagrus fulvidraco IgM monoclonal antibody comprises three sequences shown in SEQ ID NO.4-6; the mouse anti-pelteobagrus fulvidraco IgM monoclonal antibody can be obtained by being secreted by a hybridoma cell strain PFM-1B7C12A1B2 with the preservation number of CCTCC (China Center for Type Culture Collection) NO: C2024234. The mouse anti-pelteobagrus fulvidraco IgM monoclonal antibody provided by the invention can be used for Western blot and ELISA specific detection of IgM in a pelteobagrus fulvidraco secretion form, and can be used for flow cytometry identification of pelteobagrus fulvidraco IgM + B cells. The monoclonal antibody is good in specificity, high in sensitivity and strong in affinity, can be used for structural analysis, immune response level detection and the like of pelteobagrus fulvidraco IgM, and lays a foundation for in-depth study of a pelteobagrus fulvidraco immune system and establishment of a vaccine immune effect evaluation method taking the antibody level as an index.
Owner:HUAZHONG AGRI UNIV +1

Stealth lipid nanoparticle compositions for cell targeting

The present disclosure provides bispecific stealth lipid nanoparticle (LNP) compositions engineered to target specific tissues or cell-types, e.g., immune effector cells such as T cells, B cells, natural killer cells, and dendritic cells, to modify the cells with therapeutic nucleic acid encapsulated in the LNP. The present disclosure also provides compositions and methods of making the LNPs and treatment using the same.
Owner:GENERATION BIO CO

Bispecific nano antibody for targeting B cells and application of bispecific nano antibody

The invention belongs to the technical field of biology, and discloses a bispecific nano antibody targeting B cells and application of the bispecific nano antibody. The bispecific nano-antibody comprises at least one nano-antibody for recognizing a target point BCMA and one nano-antibody for recognizing a target point CD20. The nano antibody provided by the invention can be specifically combined with B cells in human blood, especially activated plasma cells, by recognizing BCMA and / or CD20 on the surfaces of the B cells, so that the B cells generating pathological antibodies are removed. The nano antibody provided by the invention has the advantages of smaller molecular weight, strong stability, low cost, easy expression and high expression quantity, and is suitable for large-scale production. The nano antibody is combined with the solid-phase carrier, B cells in blood can be cleared in a targeted mode, the number of the B cells in the blood of a patient can be reduced in a short time, the antibody level can be reduced, therefore, the life quality is improved, complications are reduced, and a new treatment choice is provided for the patient who is ineffective or intolerant to traditional treatment.
Owner:GUANGZHOU KONCEN BIOSCI

Antibody for resisting CD19 on porcine B cell surface or antigen binding fragment thereof as well as composition and application thereof

The invention provides an antibody for resisting CD19 on the surface of a porcine B cell or an antigen binding fragment thereof as well as a composition and application thereof. Specifically, the invention provides an anti-porcine B cell surface CD19 antibody or an antigen binding fragment thereof, which can effectively bind to CD19 on the porcine B cell surface. The invention also provides an antibody drug conjugate containing the antibody or the antigen binding fragment thereof, and the antibody drug conjugate can be applied to screening of porcine B cells and marking of CD19 antigens on the surfaces of the porcine B cells, and has a good application prospect.
Owner:INST OF HEALTH & MEDICINE HEFEI COMPREHENSIVE NAT SCI CENT

Use of dual-target car-t cells in treating b-cell autoimmune diseases

The use of dual-target CAR-T cells in treating systemic lupus erythematosus and other B-cell autoimmune diseases is provided. The first target of the chimeric antigen receptor is CD19, the second target is BCMA, and specifically, the chimeric antigen receptor is a chimeric antigen receptor with a Loop structure, which is shown as follow: L-VL, CD19-VH, BCMA-VL, BCMA-VH, CD19-H-TM-C-CD3ζ; the BCMA-CD19 CAR-T cells transduced by the chimeric antigen receptor targeting CD19 and BCMA can completely block the pathway of producing autoantibodies, and completely cover the B cells, plasmablasts and plasma cells at multiple differentiation stages that produce autoantibodies, so that the dual-target CAR-T therapy designed based on this concept can be aimed at refractory SLE and is expected to achieve faster remission and deeper and lasting curative effect.
Owner:GRACELL BIOTECHNOLOGIES (SHANGHAI) CO LTD

Chicken infectious anemia virus subunit vaccine

The invention discloses a chicken infectious anemia virus subunit vaccine, and belongs to the technical field of animal disease vaccines. The invention provides a chicken infectious anemia virus subunit vaccine. Active ingredients of the chicken infectious anemia virus subunit vaccine are recombinant fusion protein of chicken infectious anemia virus VP1 protein B cell epitope and salmonella typhimurium flagellin. The B cell epitope of the chicken infectious anemia virus VP1 protein is obtained by connecting B cell antigen epitopes contained in the chicken infectious anemia virus VP1 protein through a connecting peptide. The salmonella typhimurium flagellin is obtained by deleting a hypervariable region of the salmonella typhimurium flagellin FliC. The fusion expression protein provided by the invention can induce generation of a specific IgG antibody after one-day-old SPF chicken, and after immunization for 28 days, immunized chicken flocks can resist challenge of chicken infectious anemia virus virulent strains, and 70% of challenge chicken flocks are protected without disease attack. The invention has great potential for clinical prevention and control of chicken infectious anemia virus infection.
Owner:JINYU YOUBANG BIOTECHNOLOGY (JIANGSU) CO LTD

Preparation method and application of autoreactive animal model

PendingCN120519516ACompounds screening/testingHydrolasesDiseaseAntibody Classes
The invention discloses a preparation method and application of a self-reactive animal model. An autoreactive animal model is constructed based on an SWHEL system, it is found through the model that MTCH2 is a key target for regulating and controlling B cell autoreactivity, deletion of MTCH2 will cause generation of a large number of autoreactive B cells subjected to antibody category conversion, the disease risk is increased, and a basis is provided for research of B cell autoreactivity related mechanisms.
Owner:BEIJING HOSPITAL

End-to-end B cell clone pedigree forest construction method and related equipment

ActiveCN121438931AData visualisationBiostatisticsAlgorithmCognitive efficiency
The embodiment of the invention provides an end-to-end B cell clone pedigree forest construction method and related equipment, and can be applied to the technical field of data processing. According to the method, a plurality of obtained receptor sequencing sequences are subjected to germline comparison identification to obtain a first test Fv sequence corresponding to each receptor sequencing sequence, and a germline Fv sequence corresponding to each receptor sequencing sequence is generated; performing integrity filtering on the first test Fv sequence, performing clone type division to obtain a plurality of first clone type sets, constructing corresponding first evolutionary trees to form a first pedigree forest on the basis of a second clone type set contract type conversion probability, and performing node optimization on all the first evolutionary trees to obtain a second pedigree forest; and after it is determined that the homotype category conversion probability after updating based on all the second evolutionary trees meets the preset requirement, visualization processing is performed on all the second evolutionary trees, so that the systematic cognition efficiency of related personnel on the adaptive immune response mechanism can be improved.
Owner:广州赛业百沐生物科技有限公司

Anti-rabbit IgG goat recombinant monoclonal antibody as well as preparation and application thereof

The invention discloses an anti-rabbit IgG goat recombinant monoclonal antibody as well as preparation and application thereof, and belongs to the technical field of biology. The recombinant monoclonal antibody is obtained by taking purified rabbit serum IgG as an immunogen, immunizing a goat, carrying out specific B cell screening and RT-PCR (Reverse Transcription-Polymerase Chain Reaction) to obtain a heavy chain variable region and a light chain variable region of the antibody, respectively inserting sequences of the variable regions into vector plasmids with constant region (heavy chain and light chain) genes, transfecting, expressing and purifying. The recombinant monoclonal antibody provided by the invention has high affinity with rabbit IgG, can recognize and detect rabbit IgG with high specificity and high sensitivity, can be used as a secondary antibody after HRP crosslinking, is applied to detection of rabbit IgG by methods such as western blot, immunohistochemistry and ELISA, is beneficial to obtaining more accurate detection and evaluation results, and has good application prospects. And the detection cost and the interference of background signals are reduced.
Owner:HANGZHOU STAR BIOTECHNOLOGY CO LTD +1

A monoclonal antibody against human hepatitis B e antigen and its application

This invention discloses a monoclonal antibody against human hepatitis B e antigen and its application, relating to the field of hepatitis B detection technology. In the heavy chain variable region of the monoclonal antibody, the amino acid sequences of the complementarity-determining regions (CDR1-3) are as shown in SEQ ID NO. 1-3 or have at least 95% homology with the sequences shown in SEQ ID NO. 1-3; in the light chain variable region, the amino acid sequences of the complementarity-determining regions (CDR1 and CDR3) are as shown in SEQ ID NO. 4 and 5 or have at least 95% homology with the sequences shown in SEQ ID NO. 4 and 5, and the amino acid sequence of the complementarity-determining region (CDR2) is FAS. The monoclonal antibody provided by this invention can effectively recognize natural hepatitis B e antigen, and the titer of the supernatant from B cell culture can reach 1:10000, making it fully applicable to the detection and research of human hepatitis B e antigen. The chemiluminescent reagent prepared using the monoclonal antibody described in this invention has advantages such as high specificity, strong anti-interference ability, high detection sensitivity, and good stability, with almost no missed detections, and can replace imported reagents.
Owner:武汉勖瑞生物科技有限责任公司

Use of dual-target CAR-T cells in treating B-cell autoimmune diseases

A bispecific or dual target CAR or CAR-T cells can be used to treat and / or prevent an autoimmune disease. The bispecific CAR may target CD19 and BCMA. The CAR may have a loop structure, which is shown as follow: L-VL, CD19-VH, BCMA-VL, BCMA-VH, CD19-H-TM-C-CD3ζ; the BCMA-CD19 CAR-T cells transduced by the chimeric antigen receptor targeting CD19 and BCMA can completely block the pathway of producing autoantibodies, and completely cover the B cells, plasmablasts and plasma cells at multiple differentiation stages that produce autoantibodies, so that the dual-target CAR-T therapy designed based on this concept can be aimed at refractory SLE and is expected to achieve faster remission and deeper and lasting curative effect.
Owner:GRACELL BIOSCIENCE (SHANGHAI) CO LTD

Application of reagent for detecting GPR174 gene expression level in CD4 + T cell and / or B cell in preparation of product for detecting toxic diffuse goiter

The invention discloses application of a reagent for detecting GPR174 gene expression level in CD4 + T cells and / or B cells in preparation of a product for detecting toxic diffuse goiter. The invention provides a detection marker for a toxic diffuse goiter (Graves disease). The detection marker is GPR174 expressed in a CD4 + T cell or a B cell. Experiments prove that compared with healthy people, the expression of GPR174 in CD4 + T cells or B cells in the body of a Graves disease patient is remarkably up-regulated, and the expression level of GPR174 in the CD4 + T cells and the B cells is in positive correlation with the levels of Graves disease thyroid functions FT3 (free triiodothyronine), FT4 (free tetraiodothyronine) and an autoantibody TSAb (thyroid stimulating hormone receptor stimulating antibody). The expression level of the GPR174 in the CD4 + T cell and the B cell is highly related to the occurrence of the Graves disease, and the expression level of the GPR174 in the CD4 + T cell and the B cell can be used as a detection indication of the Graves disease, so that a new thought is provided for detection and treatment of the Graves disease.
Owner:SHANGHAI FIRST PEOPLES HOSPITAL

Multifunctional molecules comprising g6b binder and / or CD34 binder and uses thereof

Multispecific molecules that include an anti-G6B antibody or binding fragment thereof, an anti-CD34 antibody or binding fragment thereof; and one, two or all of: an immune cell engager (e.g., selected from an NK cell engager, a T cell engager, a B cell engager, a dendritic cell engager, and a macrophage cell engager); a cytokine molecule; a modulator of a cytokine molecule; a stromal modifying moiety; or any combination thereof are disclosed. Additionally disclosed are nucleic acids encoding the same, and methods of treating conditions or diseases using the aforementioned molecules.
Owner:MARENGO THERAPEUTICS INC

Neutralizing antibody GR12 for resisting novel coronavirus SARS-CoV-2 and variant and application of neutralizing antibody GR12

The invention discloses a novel coronavirus neutralizing antibody, a detection kit and application of the novel coronavirus neutralizing antibody. The amino acid sequence of a heavy chain variable region of the neutralizing antibody is shown as SEQ ID No.1, and the amino acid sequence of a light chain variable region of the neutralizing antibody is shown as SEQ ID No.2. The antibody with mature affinity is screened through bioinformatics analysis of a single B cell, the antibody screening process is optimized by combining single cell RNA sequencing, VDJ rearrangement analysis and somatic cell hypermutation research, blindness of a traditional method is avoided, and the accuracy and effectiveness of antibody screening are improved. According to the neutralizing antibody GR12 provided by the invention, a heavy chain variable region and a light chain variable region of the neutralizing antibody GR12 can be specifically combined with an RBD structural domain of the SARS-CoV-2 and an S-Trimer structural domain of an Omicro variant, so that a broad-spectrum neutralizing effect on the SARS-CoV-2 virus and the variant thereof is realized. The binding activity of the antibody GR12 to S-Trimer and RBD under 2-fold and 300-fold dilution conditions is obviously superior to that of other antibodies, which indicates that the antibody GR12 has high affinity and dilution stability and is suitable for clinical large-dose administration.
Owner:BEIJING YOUAN HOSPITAL CAPITAL MEDICAL UNIV +1

Biomarker for predicting drug resistance of bruton's tyrosine kinase inhibitors and application thereof

A biomarker for predicting drug resistance of a BTK inhibitor and an application thereof are provided in the present disclosure, relating to the technical field of biomedicine. The biomarker is SMPD1 or SPHK1; the drug resistance of BTK inhibitor refers to the drug resistance of diffuse large B cell lymphom cells to the BTK inhibitor. This biomarker is used to predict sensitivity of diffuse large B cell lymphom cells to the BTK inhibitors.
Owner:BEIJING FRIENDSHIP HOSPITAL CAPITAL MEDICAL UNIV

Method for detecting EBV latent infection of epithelial cells and B cells in thymus and salivary gland tissue microenvironment

The invention relates to a detection kit and a detection method for EBV latent infection of epithelial cells and B cells in a thymus and salivary gland tissue microenvironment, and the detection method comprises the following steps: dyeing thymus and salivary gland tissues by coupling quantum dots and a specific antibody; the conjugate of the quantum dots and the specific antibody is combined with a specific antigen of a tissue sample to realize marking of EBV latent infection epithelial cells and B cells by the quantum dots. According to the invention, the existing multicolor immunofluorescence technology is improved, the specific antibody and the quantum dot are coupled and purified and then are directly combined with the antigen on the tissue slice to realize direct marking of the quantum dot coupled antibody on the tissue sample, so that EBV latent infection cells in the thymus and salivary gland tissue microenvironment are positioned and quantified; the virus infection condition of the patient is evaluated from the pathogenesis level, the disadvantage that the previous evaluation means are limited is overcome, and the method has good sensitivity and accuracy.
Owner:TIANJIN MEDICAL UNIV GENERAL HOSPITAL AIRPORT HOSPITAL

Depression diagnosis marker and application thereof

The invention provides a depression diagnosis marker which is selected from one or more of immune cell Trem1 classical mononuclear cells, B cells, CD36 mononuclear cells, HLADR mononuclear cells, Th17, Treg, cell factors CXCL14, VEGFR1IL-1, RII, RANK, XEDAR, GITR, CRTAM, IL-11, IGFBP-2 and Fetuin A. The depression diagnosis marker has high MDD curative effect prediction efficiency. The invention further discloses application of the depression diagnosis marker in preparation of products for diagnosing depression, and the depression diagnosis marker has high MDD diagnosis value.
Owner:SHANGHAI MENTAL HEALTH CENT (SHANGHAI PSYCHOLOGICAL COUNSELLING TRAINING CENT) +1

Neutralizing antibody GR75 for resisting novel coronavirus SARS-CoV-2 and variant and application of neutralizing antibody GR75

The invention discloses a novel coronavirus neutralizing antibody, a detection kit and application of the novel coronavirus neutralizing antibody. The amino acid sequence of a heavy chain variable region of the neutralizing antibody is shown as SEQ ID No.1, and the amino acid sequence of a light chain variable region of the neutralizing antibody is shown as SEQ ID No.2. The antibody with mature affinity is screened through bioinformatics analysis of a single B cell, the antibody screening process is optimized by combining single cell RNA sequencing, VDJ rearrangement analysis and somatic cell hypermutation research, blindness of a traditional method is avoided, and the accuracy and effectiveness of antibody screening are improved. According to the neutralizing antibody GR75 provided by the invention, a heavy chain variable region and a light chain variable region of the neutralizing antibody GR75 can be specifically combined with an RBD structural domain of the SARS-CoV-2 and an S-Trimer structural domain of an Omicro variant, so that a broad-spectrum neutralizing effect on the SARS-CoV-2 virus and the variant thereof is realized. The binding activity of the antibody GR75 to S-Trimer and RBD under 2-fold and 300-fold dilution conditions is obviously superior to that of other antibodies, which indicates that the antibody GR75 has high affinity and dilution stability and is suitable for clinical large-dose administration.
Owner:BEIJING YOUAN HOSPITAL CAPITAL MEDICAL UNIV +1

Neutralizing antibody GR46 for resisting novel coronavirus SARS-CoV-2 and variant and application of neutralizing antibody GR46

The invention discloses a novel coronavirus neutralizing antibody GR46, a detection kit and application of the novel coronavirus neutralizing antibody GR46. The amino acid sequence of a heavy chain variable region of the neutralizing antibody is shown as SEQ ID No.1, and the amino acid sequence of a light chain variable region of the neutralizing antibody is shown as SEQ ID No.2. The antibody with mature affinity is screened through bioinformatics analysis of a single B cell, the antibody screening process is optimized by combining single cell RNA sequencing, VDJ rearrangement analysis and somatic cell hypermutation research, blindness of a traditional method is avoided, and the accuracy and effectiveness of antibody screening are improved. According to the neutralizing antibody GR46 provided by the invention, a heavy chain variable region and a light chain variable region of the neutralizing antibody GR46 can be specifically combined with an RBD structural domain of the SARS-CoV-2 and an S-Trimer structural domain of an Omicro variant, so that a broad-spectrum neutralizing effect on the SARS-CoV-2 virus and the variant thereof is realized. The binding activity of the antibody GR46 to S-Trimer and RBD under 2-time and 300-time dilution conditions is obviously superior to that of other antibodies, which indicates that the antibody GR46 has high affinity and dilution stability and is suitable for clinical large-dose administration.
Owner:BEIJING YOUAN HOSPITAL CAPITAL MEDICAL UNIV +1

Methods and compositions for using plasma cell depleting agents and / or b cell depleting agents to suppress host Anti-AAV antibody response and enable AAV transduction and re-dosing

Provided herein are methods of inserting a nucleic acid encoding a polypeptide of interest into a target genomic locus in a cell or a population of cells in a subject, methods of expressing a polypeptide of interest from a target genomic locus in a cell or a population of cells in a subject, methods of treating an enzyme deficiency in a subject in need thereof, and methods of preventing or reducing the onset of a sign or symptom of an enzyme deficiency in a subject in need thereof. Some methods, such as when a subject has preexisting against an immunogen to be administered, use plasma cell depleting agents or combinations comprising plasma cell depleting agents to mitigate immune response and facilitate redosing of nucleic acid constructs encoding a polypeptide of interest and nuclease agents targeting a target genomic locus to achieve, for example, a step-wise increase in expression of a polypeptide of interest in a subject following insertion of the nucleic acid construct without overshooting. Other methods, such as when a subject has no preexisting immunity against an immunogen to be administered, use B cell depleting agents (e.g., anti-CD20xCD3 antibody or functional fragment thereof) to mitigate immune response and facilitate redosing of nucleic acid constructs encoding a polypeptide of interest and nuclease agents targeting a target genomic locus to achieve, for example, a step-wise increase in expression of a polypeptide of interest in a subject following insertion of the nucleic acid construct without overshooting.
Owner:REGENERON PHARMACEUTICALS INC

Methods and compositions for inducing hematopoietic cell differentiation

In various aspects, the invention provides culture platforms, cell culture media, and methods of differentiating pluripotent cells into hematopoietic cells. In certain aspects, the invention also provides pluripotent stem cell-derived hematopoietic cells generated using the media and methods disclosed herein. The pluripotent stem cell-derived permanent HE cells produced by the methods provided herein are capable of differentiating into hematopoietic lineage cells comprising T cell progenitor cells and T cells in addition to NK cell progenitor cells, NK cells, NKT cells, or B cells.
Owner:FATE THERAPEUTICS INC

Monoclonal antibody for resisting mandarin fish immune globulin D (IgD) as well as preparation method and application of monoclonal antibody

The invention belongs to the technical field of immunology, and particularly relates to an anti-mandarin fish immune globulin D (IgD) monoclonal antibody as well as a preparation method and application thereof. The invention provides a hybridoma cell strain 5C7 capable of secreting an anti-fish IgD monoclonal antibody or an antigen binding fragment thereof for the first time, the hybridoma cell strain 5C7 is preserved in China Center for Type Culture Collection on January 16, 2025, and the preservation number is CCTCC NO: C202550. The anti-mandarin fish IgD monoclonal antibody or the antigen binding fragment thereof can be subjected to specific reaction with mandarin fish secreting type IgD protein and B cell surface film type IgD, can be applied to detection of IgD in a mandarin fish serum sample, and can also be applied to detection of IgD + B cell surface markers.
Owner:SUN YAT SEN UNIV

Goose astrovirus type 2 monoclonal antibody and antigen epitope peptide thereof

The invention discloses a type 2 GAstV capsid protein monoclonal antibody and an antigen epitope peptide of the type 2 GAstV capsid protein monoclonal antibody. The monoclonal antibody is prepared by immunizing a mouse with capsid protein GAstV Cap of the type 2 goose astrovirus as an antigen, and is named as 1F1; the monoclonal antibody 1F1 comprises a heavy chain variable region and a light chain variable region, and the amino acid sequences of the heavy chain variable region and the light chain variable region are sequentially shown as SEQ ID No.3 and SEQ ID No.5. In order to determine the B cell antigen epitope of the screened monoclonal antibody, the invention also constructs a GAstV Cap truncated fusion protein, and the antigen recognition epitope is determined through indirect ELISA and Western blotting tests, so that screening is carried out step by step until the shortest linear epitope recognized by the monoclonal antibody is determined, and the amino acid sequence of the shortest linear epitope is shown as SEQ ID No.10. Therefore, the monoclonal antibody and the antigen epitope of the monoclonal antibody can be applied to research on structures and functions of GAstV capsid proteins and preparation of serological diagnostic tools and epitope vaccines.
Owner:SICHUAN AGRI UNIV

Dosing for treatment with anti-CD20 / anti-CD3 bispecific antibodies

The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a B cell proliferative disorder by intravenous administration of an anti-CD20 / anti-CD3 bispecific antibody (e.g., mosunetuzumab).
Owner:GENENTECH INC